the Impact of Paediatric Use of Proton Pump Inhibitors on the Risk of Community Acquired Infections.

Centre Hospitalier Universitaire Dijon290,286 enrolled

Overview

Pharmacological treatment of physiologic Gastro-esophageal Reflux disease (GERD) is excessive in France, as 65%-85% of children below 11 years are being treated, frequently with Proton Pump Inhibitors (PPIs) PPI have been associated, in adults, with an increase of infection rate but data in pediatry are scarce, especially in community medecine. Recently a study conducted in England brought up controversial results suggesting that the use of PPIs can be associated with a reduced risk of community acquired pneumonia. Our study was aimed to assess, on a population-based database, the association between PPI prescription and community infections in children of 11 years or under.

Study Type

OBSERVATIONAL

Enrollment

290,286

Conditions

Community Infections

Interventions

all children with at least one prescription of PPIOTHER

all children with at least one prescription of PPI

Eligibility

Sex: ALLMax age: 11 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children aged 11 years or below with at least 2 consultations during the follow up Exclusion Criteria: * chronic pulmonary or cardiac * muscoviscidosis * immunodeficiency * H. pylori infection * Diabetes * Denutrition * known digestive upper tract malformation

Outcomes

Primary Outcomes

Number of overall infections

Comparison of number of infections between PPI exposed and non-exposed children. All infections are taken in account

Time frame: 4 years

Secondary Outcomes

Number of specific infections

Comparison of number of infections between PPI exposed and non-exposed